Molecular and Clinical Advances in Kidney Cancer
A special issue of Medical Sciences (ISSN 2076-3271). This special issue belongs to the section "Cancer and Cancer-Related Research".
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 12318
Special Issue Editors
Interests: renal cell carcinoma; drug development
Special Issue Information
Dear Colleagues,
Renal cell carcinoma accounts for approximately 4% of all malignant tumors with 431,288 new cases and 179,368 deaths annually worldwide (GLOBOCAN 2020). In most regions, an increase in the incidence of kidney cancer is observed, and this tumor could enter the top five most common solid tumors in men in 15 years.
Half of the patients have an advanced disease that requires systemic therapy. Currently, there is progress in the treatment of metastatic renal cell carcinoma associated with the discovery of novel targets and evaluation of the role of the immune response. Despite significant advances, less than 50% of patients with metastatic disease survive 5 years. Therefore, further research into the pathogenesis of kidney cancer is important.
This Special Issue aims to provide an update on the challenges of molecular and cellular advances in kidney cancer and highlight its expanding horizons. We invite authors to publish their original papers on basic and clinical research that evaluates new mechanisms, biomarkers, potential targets, the role of the microenvironment, and other important issues related to kidney cancer.
Dr. Ilya V. Tsimafeyeu
Dr. Petr Makhov
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- renal cell carcinoma
- clear-cell RCC
- papillary RCC
- chromophobe RCC
- rare types of kidney cancer
- hereditary RCC
- pathogenesis
- pathology
- biomarkers
- new targets
- immune system
- targeted therapy
- checkpoint inhibitors
- vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
